Clinical Trial: NCT06745804
Study of 68Ga-R10602
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Radionetics Oncology |
| Information Provided By: | Radionetics Oncology |
| Last Update Posted: | 2026-07-06 |
Study Overview
Brief Summary
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Official Title
Phase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer
Conditions
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma
Intervention / Treatment
- Drug: 68Ga-R10602 injection
Other Study ID Numbers
- R10602-101
Start Date (Actual)
2024-12-10
Primary Completion Date (Actual)
2026-05-04
Study Completion Date (Actual)
2026-05-04
Enrollment (Actual)
27
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Radionetics Oncology |
| Information Provided By: | Radionetics Oncology |
| Last Update Posted: | 2026-07-06 |
Study Overview
Brief Summary
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Official Title
Phase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer
Conditions
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma
Intervention / Treatment
- Drug: 68Ga-R10602 injection
Other Study ID Numbers
- R10602-101
Start Date (Actual)
2024-12-10
Primary Completion Date (Actual)
2026-05-04
Study Completion Date (Actual)
2026-05-04
Enrollment (Actual)
27
Study Type
Interventional
Phase
Phase 1